secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2024-03-18T23:59:59+00:00
Accession:  0001655759-24-000033
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas appoints Noah Berkowitz as Chief Medical Officer, replacing Ron Peck
----------------------------------------------------------------------------

- Noah Berkowitz, M.D., Ph.D., appointed CMO effective March 18, 2024, succeeding Ron Peck, M.D.
- Berkowitz brings 20+ years of experience, most recently as SVP at Bristol-Myers Squibb in hematology.
- He will lead clinical development of Arvinas' PROTAC protein degrader programs in oncology and neuroscience.
- Former CMO Ron Peck to remain an employee until mid-April 2024 for transition, then eligible for severance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000165575924000033/0001655759-24-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000165575924000033/arvn-20240314.htm
  HTML page:      https://secwatch.observer/filing/0001655759-24-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer